Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultralife (ULBI) Cash & Equivalents (2016 - 2025)

Ultralife (ULBI) has 15 years of Cash & Equivalents data on record, last reported at $9.3 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 36.7% year-over-year to $9.3 million; the TTM value through Sep 2025 reached $9.3 million, up 36.7%, while the annual FY2024 figure was $6.9 million, 33.31% down from the prior year.
  • Cash & Equivalents reached $9.3 million in Q3 2025 per ULBI's latest filing, down from $10.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $15.9 million in Q3 2021 and bottomed at $5.6 million in Q1 2023.
  • Average Cash & Equivalents over 4 years is $9.9 million, with a median of $9.3 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 123.64% in 2021, then crashed 33.31% in 2024.
  • A 4-year view of Cash & Equivalents shows it stood at $15.9 million in 2021, then crashed by 35.17% to $10.3 million in 2023, then plummeted by 33.31% to $6.9 million in 2024, then skyrocketed by 35.1% to $9.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $9.3 million in Q3 2025, $10.9 million in Q2 2025, and $8.7 million in Q1 2025.